Pannogel

Quick links to important sections

Pannogel

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pannogel

The following section establishes the core identity, composition, and general function of the medicine Pannogel, excluding details on dosage, administration, warnings, or specific treatment regimens.

Property Description
Active ingredient Benzoyl Peroxide (BPO)
Form Gel (Topical, semi-solid preparation)
Pharmacological Class Topical Anti-Acne Agent
General Purpose Counteracts processes that lead to skin blemishes
Origin Synthetic

What Type of Medicine is Pannogel?

Pannogel is a medicinal preparation intended for cutaneous administration, formally classified as a Topical Anti-Acne Agent. It is supplied in the specialized dosage form of a gel, a semi-solid preparation designed for direct application to the skin's surface. This product is defined by its single-ingredient status, with the sole active substance being Benzoyl Peroxide (BPO), a compound that is synthetic in origin. It is commercially positioned as an effective non-prescription option for external use.

The classification as a topical anti-acne agent signifies its role as a targeted external treatment. The gel formulation utilizes an aqueous base that helps deliver the active component effectively, which is preferred for maintaining a non-occlusive profile on the skin.

The Composition and Purpose of Pannogel: Benzoyl Peroxide

The essential constituent and active ingredient [INN] in Pannogel is Benzoyl Peroxide (BPO). Chemically, BPO is a potent oxidizing agent, and its inclusion dictates the preparation's therapeutic identity and general purpose. It is incorporated into an aqueous gel base containing excipients that ensure the appropriate contact of the active substance with the skin.

The general purpose of this topical preparation is rooted in its established dual mechanism principle: it acts as both an antimicrobial agent and a keratolytic agent. The Benzoyl Peroxide component helps to reduce the bacterial population associated with irritation and clear the debris that leads to clogged pores and lesion formation, thereby providing the foundational benefit of disrupting the progression of the condition.

What side effects are possible with Pannogel?

Possible Side Effects and Safety Information

The official safety profile for Pannogel (Benzoyl Peroxide) primarily documents localized, application-site reactions, with systemic effects being rare. These effects are classified based on frequency as listed in government regulatory documents.


Frequency-Classified Adverse Reactions

The most frequent side effects are related to the skin and are classified as follows:

Classification Common Reactions (Skin and Subcutaneous Tissue Disorders)
Very Common (ge 1 in 10) Application site erythema (redness)
Common (ge 1 in 100 to < 1 in 10) Application site pain, skin dryness, burning sensation, scaling, or peeling

These localized skin effects are noted in regulatory safety data as being most prominent at the beginning of treatment and typically decrease with continued use as the skin adapts.


Serious Safety Considerations

While absorption is minimal, the official safety documentation includes the potential for rare but serious reactions classified under Immune System Disorders. These are severe allergic reactions, which may manifest as facial swelling, rash, or difficulty breathing, and are documented as a serious safety concern.

Safety-Related Restrictions: The medication is formally contraindicated in individuals with a known hypersensitivity or allergy to Benzoyl Peroxide. Cautions are generally advised for use during pregnancy and lactation due to limited systemic data, and the safety has typically not been established for use in children under 12 years of age.

Overdose and Emergency Response

The regulatory overdose profile for Pannogel (Benzoyl Peroxide topical gel) is defined by two primary risk contexts: localized effects resulting from excessive local application and the risk of rare, severe systemic hypersensitivity reactions.

Overdose Context Officially Documented Manifestations Regulator-Mandated Action
Excessive Topical Use Severe local irritation, severe erythema (redness), dryness, peeling, blistering, or swelling of the treated area. Discontinue use of the product and institute appropriate symptomatic and supportive therapy.
Life-Threatening Reaction Rare, serious hypersensitivity, including throat tightness, difficulty breathing, feeling faint, or swelling of the face, eyes, lips, or tongue. Seek emergency medical attention immediately and stop using the product without delay.

The documented clinical manifestations of over-application primarily affect the cutaneous system. If these severe localized symptoms develop, official labeling instructs users to cease application of the gel and manage the irritation with supportive measures. The most critical regulatory requirement is the immediate seeking of emergency care for any sign of a systemic reaction, as these events are documented as potentially life-threatening. The official prescribing information confirms that no specific antidote is known for the treatment of Benzoyl Peroxide overdose.

Therapeutic Uses of Pannogel

Pannogel is commonly used in the symptomatic management of conditions involving inflammatory or irritative processes, such as mild to moderate acne. This topical agent is applied across therapeutic domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations of acne. It is considered relevant for adolescents and adults, and supports patients during difficult episodes by assisting with managing patient discomfort associated with visible symptoms on the face, back, or chest.

Treatment for Mild to Moderate Acne

This medicine is relevant for the management of both inflammatory lesions (such as redness, swelling, and pustules) and noninflammatory lesions (such as blackheads and whiteheads). The preparation is relevant when supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable, where it contributes to improved comfort. When used in the management of these initial lesions, the preparation assists with maintaining functional stability and may assist with managing the formation of new spots.


Quick Fact: Relief for Inflammatory Symptoms

Pannogel is commonly used to help ease the physical discomfort and visible prominence of red, swollen bumps that characterize inflammatory breakouts.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Pannogel?

The population eligibility for Pannogel (Benzoyl Peroxide Gel) is strictly defined by government regulatory documents, focusing on age, known allergies, and specific physical conditions. Use of the medicine is contraindicated in patients with a known history of hypersensitivity or allergy to Benzoyl Peroxide or any other ingredient in the formulation.


Eligibility Status by Population

Population Group Regulatory Status
Adults and Adolescents (typically ge 12 years) Allowed/Approved
Children under 12 years Not Established/Not Recommended
Geriatric Patients Not Established
Pregnant Patients Conditional Use (Only if clearly needed)
Breastfeeding Patients Conditional Use (Avoid application to the chest area)

Application Restrictions

The gel must not be applied to compromised skin areas, including broken skin, cuts, abrasions, sunburned skin, or skin affected by eczema. This restriction relates to the local integrity of the application site.

No specific systemic contraindications are documented for patients with severe renal or hepatic impairment due to the minimal systemic absorption of the topical active ingredient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of topical Pannogel (Benzoyl Peroxide) primarily through localized, pharmacodynamic effects, rather than systemic interactions.

Documented Interaction Patterns

Classification Interacting Entity Interaction Outcome Stated in Label
Efficacy/Pharmacodynamic Topical Retinoids (e.g., Tretinoin, Tazarotene) Co-administration is restricted as Benzoyl Peroxide may reduce their efficacy and increase the risk of cumulative irritation.
Additive Local Effects Other Peeling or Abrasive Topical Products Concomitant use must be avoided due to the official risk of an additive irritant effect.
Localized Chemical Reaction Topical Sulfonamide-Containing Products Co-application may result in a temporary discoloration (yellow or orange) of the skin and hair.

Systemic Interaction Status

Official prescribing information confirms that systemic pharmacokinetic interactions with oral or systemic medicinal products, including those mediated by CYP enzymes or drug transporters, are unlikely to occur.

This status is due to the low percutaneous absorption of the active ingredient and its rapid, local metabolism to benzoic acid, meaning the active substance is not present in the bloodstream at levels high enough to alter the clearance or exposure of other medicines.

Mechanism of Action

How Pannogel Works

Pannogel's active component, benzoyl peroxide, acts via a dual pharmacodynamic strategy, engaging pathways that involve free radical generation and influence epidermal cell turnover. This mechanism results in physicochemical alterations to the local follicular environment.


Microbial Reduction via Free Radical Generation

Pannogel's action is initiated by the decomposition of benzoyl peroxide, involving the cleavage of the peroxide bond to form benzoyloxy free radicals. This engages a mechanism that nonspecifically interacts with bacterial proteins, primarily targeting Cutibacterium acnes within the pilosebaceous unit. This cascade results in a diminished bacterial population density within the follicular lumen.


Enhancing Epidermal Cell Desquamation

The drug modulates key pathways associated with the epithelial growth and differentiation process. This is achieved through keratolytic effects that support the alteration of cellular signaling patterns, which subsequently increases the desquamation rate of corneocytes. This modification of early molecular steps reduces the accumulation of keratin and lipid components within the pilosebaceous unit, generating physicochemical alterations that loosen the follicular plug.

Dosage and Administration Information

Official Administration Guidelines for Pannogel

Pannogel (Benzoyl Peroxide topical gel) is a preparation strictly intended for topical use on the skin's surface. Established usage patterns define the steps necessary for administration and the authorized dosing schedule.

The gel is typically available in concentrations ranging from 2.5% to 10%. For use, the skin must be thoroughly cleansed before a thin layer of the medication is applied to the entire affected area. Dosing is commonly initiated at once daily; official instructions permit a gradual increase to two or three times daily, if required and if the skin tolerates the frequency adjustment.

Category Official Administration Rule
Route Topical, external use only.
Application Area Cover the entire affected area (not spot treatment).
Frequency Range One to three times daily.
Age Group Adults and Children 12 years and older. Use in children younger than 12 is to be determined by a healthcare provider.

Continuous application is generally required, with maximum benefits typically becoming observable after approximately 8 to 12 weeks of consistent use. Official instructions specify that the gel must not be applied near mucous membranes, including the eyes, mouth, and lips. Additionally, contact with hair or colored fabrics must be avoided, as the active ingredient possesses a bleaching effect.

Recent Clinical Evidence

Pannogel: Recent Clinical Evidence


Evidence for Use in Mild to Moderate Acne Vulgaris

The research base for Benzoyl Peroxide, the active ingredient in Pannogel, includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews examining its use for mild to moderate acne vulgaris, a condition characterized by fluctuating symptoms.

Studies typically examined the topical agent against a vehicle or placebo, and outcomes that were studied involved counting the number of inflammatory lesions and non-inflammatory lesions to measure how these counts were recorded. Studies also monitored overall acne improvement using established scales, such as the Investigator Global Assessment (IGA), and examined patient-reported outcomes. The core evidence includes tightly controlled RCTs, a study design commonly used for clinical evaluation, that compared the Benzoyl Peroxide gel to an inactive comparator. Studies reported measurements of lesion counts and described the patterns observed in the active treatment groups, contributing to understanding how the active component was observed in these settings.


Research Limitations and Follow-up Durations

Most of the primary clinical trials assessing the main effects of Benzoyl Peroxide were conducted over short-to-intermediate time intervals, often lasting between 8 and 12 weeks. This time frame was used to measure initial differences between the groups in the outcomes being studied.

The existing studies provide limited information for long-term outcomes regarding the sustained effects of the monotherapy, and the long-term durability of the outcomes is not fully established. While Benzoyl Peroxide has been extensively studied, the research base exhibits high heterogeneity (differences in concentration, vehicle, and outcomes monitored). This variability can complicate direct comparisons, and the certainty remains low for certain head-to-head comparisons against other single-ingredient topical agents. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.


Evidence in Specific Study Populations

The majority of the published data was evaluated in general populations of adolescents and adults with mild to moderate acne. Research has explored outcomes in certain patient subgroups, including those defined by different skin types or ethnic backgrounds, though findings for these specific subgroups may be less comprehensive than the data for the overall population. Evidence for very young children or older adults remains limited, and results apply only to the populations studied.

Key Studies & References

  1. Acne Vulgaris | Benzoyl Peroxide | Adapalene | Randomized Controlled Trial - Indian Journal of Pharmaceutical Sciences

Frequently Asked Questions (FAQ)

Common questions about Pannogel (FAQ)


Q: What is the difference between the 5% strength and the 10% strength Pannogel?

A: Pannogel's active ingredient, benzoyl peroxide, is available in concentrations up to 10% in over-the-counter products. Official and medical information indicates that lower concentrations, such as 2.5% or 5%, are often described as having similar efficacy to the 10% concentration. However, lower strengths are typically associated with a lower risk of common local side effects like skin irritation, dryness, and peeling.

Q: Is a purging phase (temporary worsening of skin) common when starting Pannogel?

A: Official safety documents note that the skin condition may appear to worsen before it begins to improve during the initial weeks of using the product. This effect is generally expected, along with skin dryness and peeling, and typically decreases with continued use as the skin adjusts to the medication.

Q: What kind of dryness or peeling is considered normal when using Pannogel?

A: Dryness, scaling, or peeling are among the most frequently reported local side effects, particularly when treatment begins. These effects are generally expected to be mild to moderate. If the symptoms become severe or bothersome, official instructions indicate that a temporary reduction in application frequency may be necessary.

Q: Can Pannogel be used during the summer months?

A: Official regulatory cautions advise users to minimize time in the sun, avoid sunlamps, and avoid tanning beds during treatment. This is because the active ingredient may increase the skin's sensitivity to sunlight. Regulatory-linked information indicates that a sunscreen and protective clothing are generally advised when outdoors.

Q: Are there any specific sun sensitivity warnings for people using Pannogel?

A: Yes, regulatory-sourced information includes a specific warning that the active ingredient may increase the skin's sensitivity to the sun (photosensitivity). Official guidance suggests precautions such as minimizing sun exposure and using protective measures like sunscreen and clothing are typically followed.

Q: Can I apply other topical medicines right after applying Pannogel?

A: Regulatory guidance often recommends avoiding the simultaneous use of other topical acne treatments or products containing strong peeling agents on the same area. This is to avoid an additive irritant effect. Non-irritating products like certain cosmetics are typically used at a separate time after the gel has dried.

Q: What are the main research themes surrounding Pannogel’s effectiveness?

A: Clinical trials and research themes examined in regulatory support documents focus on measuring the reduction in the number of acne lesions, both inflammatory and non-inflammatory. Researchers also monitor overall acne improvement using established scales, such as the Investigator Global Assessment (IGA), to track observed patterns of change.

Q: What should I do if the irritation from Pannogel is severe?

A: If irritation, redness, dryness, or peeling become severe or highly bothersome, official instructions advise that reducing the frequency of application or temporarily stopping use may be necessary. If severe irritation persists or worsens, consulting a healthcare provider for further guidance is generally indicated in official documentation.

Q: Is Pannogel the same as other medicines for acne?

A: Pannogel’s active ingredient, benzoyl peroxide, is classified as a topical anti-acne agent that acts as an antimicrobial and keratolytic (helping shed skin cells). This mechanism is distinct from other classes of acne medicines, such as topical antibiotics or topical retinoids, which operate via different primary actions.

Q: Why is Pannogel available over-the-counter (OTC) in some places but requires a prescription in others?

A: In certain regions, benzoyl peroxide up to a specific concentration is categorized under an Over-the-Counter (OTC) Monograph, allowing for non-prescription sales. However, a prescription is typically required when the active ingredient is formulated in combination with a prescription-only medicine, such as a topical antibiotic or a retinoid.

Q: Can Pannogel be used on parts of the body other than the face?

A: The medication is officially approved for the treatment of acne, which may occur on various parts of the body, including the chest or back. The general instruction is to apply a thin layer to the entire affected area, provided the skin in those areas is intact and not compromised.

Q: If I stop using Pannogel, will the skin condition come back?

A: Regulatory-linked information indicates that continuous use is generally required to maintain a satisfactory response. Discontinuation of the product will typically lead to the recurrence of the condition it is intended to manage.

Q: Does Pannogel make the skin more sensitive to cold weather?

A: Official consumer information advises that caution may be needed regarding extreme weather conditions. Strong winds or cold weather may increase skin irritation during treatment.

Q: Is it safe to use makeup or moisturizer while using Pannogel?

A: Official drug information often states that cosmetics, including makeup, can generally be used. Users are typically advised to clean the skin thoroughly before applying the medication. Moisturizers may be used to help manage the dryness and peeling that the product can cause.

Q: Can Pannogel cause redness or irritation in the eyes?

A: The official product label specifies that the gel should not be applied near mucous membranes, including the eyes. Official instructions indicate that if the medication accidentally contacts the eyes, they should be flushed with large amounts of water, and a healthcare provider should be consulted if irritation persists.

Q: Is the medication absorbed into the bloodstream when applied to the skin?

A: Regulatory documents state that only a very small amount of the active ingredient is absorbed through the skin after topical application. The absorbed portion is rapidly broken down locally into benzoic acid and is not present in the bloodstream at high levels, making systemic effects unlikely.

Q: What should I do if the area treated with Pannogel feels itchy?

A: Itching (pruritus) is documented in official safety data as a less common application site reaction that can occur. If itching is bothersome or persistent, official sources indicate that consulting a healthcare provider may be required, as itching can signal a contact sensitization reaction.

Q: Does Pannogel interact with birth control pills?

A: Official prescribing information confirms that systemic pharmacokinetic interactions with oral medicinal products, including oral contraceptives, are unlikely to occur. This is due to the minimal systemic absorption and rapid local metabolism of the active ingredient.

Q: What happens if a child accidentally swallows a small amount of Pannogel?

A: The product is strictly for external use and may be harmful if swallowed. Official instructions indicate that if the product is accidentally swallowed, immediate contact with a poison control center or a healthcare professional is generally required.

Q: Does Pannogel have any effect on skin texture beyond treating the target condition?

A: The drug's mechanism includes a keratolytic effect, which means it helps increase the shedding of dead skin cells. This process supports the alteration of the epidermal cell differentiation process, which can generally affect the appearance and feel of the skin.

Q: How does the inactive ingredient list affect how Pannogel works?

A: The inactive ingredients, or excipients, are included to create the specialized gel base. They are necessary to ensure the stability of the product and facilitate the appropriate contact and delivery of the active substance, benzoyl peroxide, to the skin’s surface.

Q: Is it normal to see some white residue after Pannogel dries?

A: The gel formulation is designed to be applied in a thin layer to the affected area. While not a documented side effect, the appearance of some visible white residue after drying may be a normal physical property of the product and may be reduced when only a thin layer is applied, as advised in the general administration instructions.

Q: Can Pannogel be used with sunscreen?

A: Yes, official guidance indicates that sunscreen is generally advised to be applied as part of a daily routine when using this product. Since the active ingredient can increase the skin’s sensitivity to sunlight, the use of an oil-free sunscreen with a high SPF is often suggested.

Q: What does the term 'non-comedogenic' mean in relation to Pannogel?

A: The term 'non-comedogenic' is often used in the context of acne treatments to describe products that are formulated to avoid blocking or clogging pores (comedones). The gel formulation is typically water-based and designed to be non-occlusive.

Q: Is Pannogel considered a first-line treatment for its primary indication?

A: Yes, official medical guidelines from authoritative bodies often recommend topical benzoyl peroxide as one of the first and most foundational treatments to be used for mild to moderate acne vulgaris.

Q: Are there any long-term safety concerns documented for Pannogel?

A: The active ingredient, benzoyl peroxide, was classified by the FDA as Generally Recognized as Safe and Effective (GRASE) after a review of safety data. The primary documented safety concerns are the predictable localized skin reactions and the potential for rare, severe allergic reactions.

Q: Do studies show that Pannogel works better in combination with another medicine?

A: Yes, studies have shown that the active ingredient may be more effective when combined with other acne treatments, particularly topical antibiotics or retinoids. Regulatory approval has been granted for several prescription combination products that contain benzoyl peroxide.

Q: Why might a patient be told to use Pannogel only for a limited time?

A: If the product is part of a combination treatment that includes a prescription antibiotic, the antibiotic component is typically used for a limited duration (e.g., 12 weeks) to reduce the risk of antibiotic resistance. However, when used as a single-ingredient product, it is generally used continuously to maintain the desired effect.

Q: Is it true that Pannogel can bleach hair or fabric?

A: Yes, official regulatory labeling includes a warning that the active ingredient, benzoyl peroxide, is an oxidizing agent. This property means that it may bleach or discolor hair and dyed fabrics, such as clothing, bedding, and towels.

Q: Can I apply moisturizer before or after Pannogel application?

A: Guidance on application timing is generally advised by healthcare providers. Some consumer sources indicate that applying moisturizer after the gel has dried can help manage skin dryness. Applying the product to thoroughly cleansed, dry skin is the standard first step before applying any other products.


How should Pannogel be stored and disposed of?

How to Store and Dispose of Pannogel

Storage and disposal of Pannogel (Benzoyl Peroxide Gel) must follow official regulatory guidelines to maintain product stability and ensure safety.

Requirement Official Storage Statement
Temperature Store at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F).
Handling Keep the container tightly closed. Avoid contact with hair and dyed fabrics, as the product will cause bleaching.
Child Safety Keep out of reach of children. Seek medical help immediately if swallowed.
Disposal Dispose of unused or expired gel according to local regulations.

Storage must prevent freezing and extreme heat, which can compromise the product's integrity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pannogel found in:

A-Z Index: